Panakeia
Panakeia
Panakeia builds an AI-driven, in‑silico multi‑omics platform that extracts comprehensive biomarker and molecular profiling directly from routine H&E tissue images. Their mission is to deliver rapid, low‑cost precision diagnostics to inform cancer treatment decisions and accelerate drug discovery by providing molecular insights (DNA, RNA, protein, metabolite and pathway activity) without additional assays or specialised equipment.
What we do
Panakeia’s flagship PANProfiler products (including PANProfiler Breast and PANProfiler Colorectal) provide molecular profiling results in minutes, enabling clinicians and researchers to make faster treatment and development decisions. The company works with NHS hospitals and international partners, holds UKCA-marked clinical products, and collaborates with organisations such as Cancer Research UK, King’s College London, PathLAKE and Leeds University.
Founded in 2018 and headquartered in Cambridge/London, Panakeia combines clinicians, scientists and engineers to scale multi‑omics for clinical and research use.
Specialties:
- Machine Learning & Deep Learning
- AI for Healthcare & Digital Pathology
- Cancer Diagnostics & Personalized Medicine
- In‑silico Multi‑omics & Biomarker Profiling